Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291321 | 0.86 | PPARG (0.57) | PPARGCAPN1MCL1KDM4EMAPT | |
| SCHEMBL1130751 | 0.70 | PPARG (0.49) | PPARGCAPN1MCL1KDM4EMAPT | |
| SCHEMBL13530152 | 0.69 | PPARG (0.60) | PPARGCAPN1MCL1KDM4EMAPT | |
| SCHEMBL21783138 | 0.66 | MCL1 (0.67) | PPARGMCL1GAAL3MBTL1MEN1 | |
| SCHEMBL14426530 | 0.66 | LMNA (0.51) | PPARGCAPN1MCL1KDM4EMAPT | |
| Glitazone SCHEMBL623021 | 0.65 | MAPT (0.73) | PPARGMAPTHPGDMEN1KMT2A | |
| SCHEMBL4834098 | 0.65 | PPARG (0.55) | PPARGCAPN1MCL1KDM4EMAPT | |
| SCHEMBL5213619 | 0.65 | MAOB (0.71) | PPARGCAPN1MAPTLMNAGLA | |
| SCHEMBL15180375 | 0.64 | CAPN1 (0.45) | PPARGCAPN1MAPTMEN1KMT2A | |
| Glitazone SCHEMBL18174924 | 0.64 | CAPN1 (0.45) | PPARGCAPN1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560956-B1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | OCTETA THERAPEUTICS LLC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-8937182-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937182-B2 | Synthesis for thiazolidinedione compounds | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130204004-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130204004-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011133442-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130204004-A1 | NOVEL SYNTHESIS FOR THIAZOLIDINEDIONE COMPOUNDS | PPARG, PPARD, PPARA | PPARG 1/4885CAPN1 4206/4885MCL1 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.